SS-31: Molecular Structure

Molecular Structure and Properties#

SS-31 (Elamipretide/Bendavia/MTP-131) is a synthetic tetrapeptide with a molecular weight of 639.8 Da and the molecular formula C32H49N9O5. Its CAS registry number is 736992-21-5. The peptide consists of four amino acid residues arranged in an alternating aromatic-cationic motif: D-Arg-Dmt-Lys-Phe-NH2, where Dmt denotes 2',6'-dimethyltyrosine. This compact structure was engineered to penetrate cell membranes, resist enzymatic degradation, and selectively accumulate within the inner mitochondrial membrane.

Szeto-Schiller Peptide Design#

The SS peptide family was developed by Hazel H. Szeto and Peter W. Schiller in the early 2000s as a class of cell-permeable mitochondria-targeted antioxidant peptides. The fundamental design principle underlying SS-31 is the alternating aromatic-cationic motif, in which aromatic residues alternate with positively charged residues in the sequence. This motif was empirically identified as conferring the ability to cross cell membranes and concentrate in mitochondria without dependence on mitochondrial membrane potential.

The independence from membrane potential is a critical distinction from other mitochondria-targeted compounds such as triphenylphosphonium (TPP) conjugates, which rely on the negative-inside electrochemical gradient across the inner mitochondrial membrane to accumulate in the matrix. In many pathological states, including ischemia-reperfusion injury, heart failure, and genetic mitochondrial diseases, mitochondrial membrane potential is depolarized or unstable. Agents that require membrane potential for uptake lose their targeting capability precisely when they are most needed. SS-31 circumvents this limitation through its amphipathic structural properties.

D-Arginine Modification#

The N-terminal residue of SS-31 is D-arginine rather than the naturally occurring L-arginine. This stereochemical inversion serves a specific pharmacological purpose: resistance to aminopeptidase degradation. Endogenous aminopeptidases recognize and cleave peptide bonds involving L-amino acids at the N-terminus. By incorporating the D-enantiomer, SS-31 evades this class of proteolytic enzymes, substantially extending its metabolic stability and circulating half-life relative to an all-L-amino-acid analog.

The guanidinium group of arginine, regardless of stereochemistry, provides a cationic charge at physiological pH. This positive charge is essential for the electrostatic interactions that drive both membrane penetration and cardiolipin binding. The guanidinium moiety is one of the most effective cationic groups for facilitating membrane translocation, as evidenced by its prevalence in cell-penetrating peptides such as the HIV TAT peptide.

2',6'-Dimethyltyrosine (Dmt) Modification#

The second residue, 2',6'-dimethyltyrosine (Dmt), is a non-natural amino acid in which the tyrosine phenol ring bears methyl groups at the 2' and 6' positions. This modification serves dual functional roles. First, the two methyl substituents increase the electron density of the phenolic hydroxyl group, enhancing its ability to donate hydrogen atoms to reactive oxygen species and thereby scavenge free radicals. This grants SS-31 intrinsic antioxidant capacity at the level of individual molecular interactions with ROS.

Second, the Dmt residue contributes to the aromatic character of the peptide that is necessary for hydrophobic interactions with the lipid bilayer of the inner mitochondrial membrane. The dimethyl groups also increase the overall lipophilicity of the residue relative to unmodified tyrosine, facilitating membrane partitioning.

C-Terminal Amidation#

The C-terminus of SS-31 is amidated (Phe-NH2) rather than bearing the free carboxylate that would be present in the natural amino acid. This modification eliminates the negative charge that a free C-terminal carboxylate would carry at physiological pH. Because SS-31 relies on its net positive charge for both membrane penetration and electrostatic binding to cardiolipin, the removal of this negative charge increases the net positive character of the molecule and improves its ability to interact with the negatively charged phospholipid headgroups of cardiolipin.

At physiological pH, SS-31 carries a net charge of approximately +3, contributed by the guanidinium of D-Arg (+1), the epsilon-amino group of Lys (+1), and the N-terminal amino group (+1). This high positive charge density in a small tetrapeptide is a defining feature of its pharmacological activity.

Cardiolipin Binding Mechanism#

The primary molecular target of SS-31 is cardiolipin, a diphosphatidylglycerol lipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin carries a net negative charge of approximately -2 at physiological pH due to its two phosphate headgroups. The binding interaction between SS-31 and cardiolipin involves both electrostatic and hydrophobic components.

The electrostatic component arises from the interaction between the cationic residues of SS-31 (D-Arg and Lys) and the anionic phosphate headgroups of cardiolipin. The hydrophobic component involves the insertion of the aromatic residues (Dmt and Phe) into the acyl chain region of the lipid bilayer. This bimodal binding anchors SS-31 within the inner mitochondrial membrane at the precise location where electron transport chain complexes reside and where ROS are generated.

The selectivity of SS-31 for cardiolipin over other phospholipids has been demonstrated through in vitro binding studies. Because cardiolipin is localized almost exclusively to the inner mitochondrial membrane and constitutes approximately 20% of its total lipid content, this binding selectivity accounts for the more than 1,000-fold concentration of SS-31 within mitochondria relative to the cytosol.

Chemical and Physical Properties#

Pharmacokinetics#

SS-31 demonstrates an elimination half-life of approximately 3 to 4 hours following subcutaneous administration in humans, based on data from clinical trial programs. This is substantially longer than would be expected for an unmodified tetrapeptide, reflecting the protective effects of the D-amino acid incorporation and C-terminal amidation against enzymatic degradation.

Following subcutaneous injection, SS-31 is rapidly absorbed into the systemic circulation and distributes to tissues with high mitochondrial density, including the heart, skeletal muscle, kidneys, and brain. The rapid cellular uptake and mitochondrial concentration of SS-31 mean that plasma levels may not fully reflect tissue and mitochondrial concentrations, as the peptide partitions out of the blood compartment and into intracellular organelles.

Intravenous administration has been used in acute clinical settings such as the EMBRACE STEMI trial, where rapid achievement of therapeutic concentrations was required at the time of coronary reperfusion. Subcutaneous administration is the standard route for chronic dosing regimens, as used in the TAZPOWER trial for Barth syndrome.

The metabolic fate of SS-31 involves proteolytic degradation to smaller peptide fragments and ultimately free amino acids. Renal and hepatic clearance both contribute to elimination. The relatively short half-life necessitates daily dosing for sustained therapeutic effect, as demonstrated in the chronic treatment protocols evaluated in clinical trials.

Structural Comparison to Other SS Peptides#

SS-31 is one of several members of the Szeto-Schiller peptide family. SS-02 (Dmt-D-Arg-Phe-Lys-NH2) shares the same four amino acid residues but in a different sequence order, demonstrating that the alternating aromatic-cationic motif rather than the specific sequence determines mitochondrial targeting. SS-20 (Phe-D-Arg-Phe-Lys-NH2) lacks the Dmt residue and therefore has reduced radical scavenging activity, while retaining mitochondrial targeting and cardiolipin binding capability. Comparative studies of SS-20 and SS-31 have helped dissect the relative contributions of direct antioxidant scavenging versus cardiolipin stabilization to the overall therapeutic effect.

These structure-activity relationships have clarified that the primary therapeutic mechanism of SS-31 is cardiolipin stabilization and electron transport chain optimization rather than direct ROS scavenging, although the Dmt residue does contribute antioxidant capacity that may provide additional benefit in acute oxidative stress conditions.

Related Reading#

• SS-31 overview and research guide
• Peptides similar to SS-31
• SS-31 research evidence